Fidelity Investments’s NewAmsterdam Pharma NAMS Stock Holding History

Fidelity Investments’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$281M	Buy	8,765,811 +2,352,827	+37%	+$76.6M	0.01%	714
2025 Q4	$225M	Buy	6,412,984 +877,691	+16%	+$31.9M	0.01%	819
2025 Q3	$157M	Buy	5,535,293 +3,630,743	+191%	+$87M	0.01%	955
2025 Q2	$34.5M	Buy	1,904,550 +940,726	+98%	+$17.2M	﹤0.01%	1522
2025 Q1	$19.7M	Buy	963,824 +963,612	+454,534%	+$21.4M	﹤0.01%	1684
2024 Q4	$5.45K	Sell	212 -330,200	-100%	-$7.01M	﹤0.01%	4651
2024 Q3	$5.48M	Buy	330,412 +86,712	+36%	+$1.5M	﹤0.01%	2101
2024 Q2	$4.68M	Hold	243,700	–	–	﹤0.01%	2098
2024 Q1	$5.76M	Buy	+243,700	New	+$4.95M	﹤0.01%	2037

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Fidelity Investments's NAMS Position: Q1 2026 in Review

Fidelity Investments increased its NewAmsterdam Pharma (NAMS) stake by 37% in Q1 2026, buying an estimated $76.6M and bringing the position to 8,765,811 shares worth $281M. The position accounts for 0.01% of the portfolio, ranked #714.

Fidelity Investments first reported a position in NAMS in Q1 2024 and has held it in 9 quarters since. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Fidelity Investments held 8,765,811 shares of NewAmsterdam Pharma worth $281M as of Q1 2026.
Fidelity Investments bought 2,352,827 NewAmsterdam Pharma shares in Q1 2026, an estimated $76.6M.
NewAmsterdam Pharma made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #714 holding.
Fidelity Investments first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 9 quarters since.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.